Pricing Log in Create free account
Friday 6 November 2026 Export NEOG’s income statement to Excel — free account

Neogen Corporation

NEOG Healthcare Medical Devices

Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.

Revenue
+6.50%
EPS
−129.4%
Free cash flow
+135.6%
Total debt
−2.31%

Quarter to August 2026, against a year earlier

11.98 0.30 +2.57%
Market cap
$2.6B
P/E
0.0×
Fwd P/E
−93.3×
Dividend yield
—
F-score
5/9
Altman Z
1.11
Beneish M
−2.43
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.01
Sold, $m 0.11
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — 2 1 — — — — — 1 — 1 —
Sell — — — — — — — — — — — 1
Insider Ownership 0.89%

Capital & Financial Ratios $m

Size
Market Cap 2,550.00
Revenue ttm 884.00
Net income ttm (56.10)
Free cash flow ttm 49.90
Net debt Q 602.20
Valuation
P/E 0.00
Forward P/E (93.30) (negative: loss-making)
Price / sales 2.88
Forward P/S Powerpack
Price / FCF 50.96
Price / book 1.22
Financial health
Current ratio Q 3.90 (at or above 1.5: strong)
Debt / equity Q 0.37 (at or below 0.5: strong)
Interest coverage Q (0.13)
Growth
Revenue growth Q +6.50% (above 0%: growing)
Operating income growth Q +88.82% (above 0%: growing)
EPS, this year +4.17%
EPS, next year A +33.00% (at or above 15%: strong)
Revenue, next year A +2.03%
EPS, past 5 yrs —
EPS, next 5 yrs A +23.31% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 6.4×; over the ten years it ranged from 2.0× in 2025 to 11.4× in 2018.
P/S against its own 10 years 16.35%
10-year low 10-year high
P/B against its own 10 years 28.49%
10-year low 10-year high
EV/Sales against its own 10 years 16.94%
10-year low 10-year high
EV/FCF against its own 10 years 43.93%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 171 129 186 172
Receivables 173 153 147 136
Inventory 189 191 144 146
Other — 50 68 70
589 577 605 583
2024 2025 2026 Q'26
Payables 83 80 79 78
ST’ Debt 2 19 — —
Other 23 39 31 34
154 174 158 150

Compound Annual Growth %

10y 5y 3y
Sales 10.48% 13.19% 1.91%
Cash Flow 8.94% 0.52% 26.57%
Earnings 0.00% 0.00% 0.00%
Book Value 17.87% 20.02% (12.59%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.05 Actual 0.08

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 0.07 0.10 Beat by 0.03
Q3 FY26 0.04 0.09 Beat by 0.05
Q4 FY26 0.05 0.09 Beat by 0.04
Q1 FY27 0.05 0.08 Beat by 0.03
Q2 FY27 0.07 — Reports 14 January 2027

EPS $

Aug Nov Feb May Year
’26 (0.05) — — — —
’26 0.17 (0.07) (0.08) (0.05) (0.04)
’25 (0.06) (2.10) (0.05) (2.82) (5.03)
’24 0.01 (0.02) (0.01) (0.02) (0.04)
’23 0.05 (0.19) 0.04 0.03 (0.12)
’22 0.16 0.10 0.05 0.14 0.45
’21 0.15 0.15 0.13 0.15 0.57
Fiscal quarters ending in the months shown.

Revenue $m

Aug Nov Feb May Year
’26 223 — — — —
’26 209 225 211 225 870
’25 217 231 221 225 895
’24 229 230 229 237 924
’23 132 230 218 242 822
’22 128 131 128 140 527
’21 109 115 117 127 468
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Aug Nov Feb May Year
’26 13 — — — —
’26 11 19 23 30 83
’25 (18) 40 19 16 58
’24 23 16 (30) 27 35
’23 (14) (19) (17) 91 41
’22 23 18 7 20 68
’21 25 22 12 22 81
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Aug Nov Feb May Year
’26 5 — — — —
’26 (13) 8 11 26 32
’25 (52) 23 (13) 1 (41)
’24 (8) (9) (62) 3 (76)
’23 (27) (30) (32) 66 (24)
’22 22 14 0 8 44
’21 21 16 3 15 54
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to May

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Aug ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 358 398 414 418 468 527 822 924 895 870 884 +10.4% 888 828 867 (0.1%)
Gross margin, % 47.15 46.81 46.34 46.94 45.91 46.10 49.36 50.19 47.10 46.93 47.40 (0.2) pt
EBT 67 73 73 72 75 60 (22) (14) (1,133) (9) (68) n/m
EBT margin, % 18.61 18.46 17.62 17.29 16.07 11.42 (2.68) (1.55) (126.65) (1.03) (7.66) (19.6) pt
Net income 44 63 60 59 61 48 (23) (9) (1,092) (8) (56) n/m
Per share, $
Per share, $ Revenue 3.54 3.87 3.99 3.98 4.40 4.90 4.35 4.27 4.12 4.00 4.05 +1.4%
Earnings 0.43 0.61 0.58 0.57 0.57 0.45 (0.12) (0.04) (5.03) (0.04) (0.25) n/m
Cash flow 0.60 0.67 0.62 0.82 0.76 0.63 0.22 0.16 0.27 0.38 0.39 (4.8%)
Capex (0.14) (0.20) (0.14) (0.23) (0.25) (0.23) (0.34) (0.51) (0.46) (0.24) (0.16) +5.6%
Free cash flow 0.45 0.47 0.47 0.59 0.51 0.41 (0.13) (0.35) (0.19) 0.15 0.23 (11.7%)
Book value 4.67 5.45 6.15 6.90 7.89 8.24 16.59 14.52 9.55 9.62 9.57 +8.4%
Shares, m 101 103 104 105 106 108 189 217 217 218 218 +8.9%
Valuation, ×
Valuation, × P/E 55.50 62.44 49.01 63.58 79.34 58.80 0.00 0.00 0.00 0.00 0.00 36.9
P/S 6.70 9.77 7.06 9.03 10.37 5.41 4.02 3.08 1.38 2.23 2.88 5.9
P/B 5.08 6.94 4.58 5.21 5.78 3.21 1.05 0.91 0.60 0.93 1.22 3.4
EV/Sales 6.29 9.24 6.41 8.21 9.56 4.68 4.80 3.86 2.23 2.95 3.58 5.8
EV/FCF 49.35 76.33 54.02 55.52 82.36 56.62 (165.10) (46.93) (48.41) 80.24 63.42 19.4
Cash, $m
Cash, $m Operating cash flow 60 69 64 86 81 68 41 35 58 83 85 +3.6%
Capex (15) (21) (15) (24) (27) (24) (65) (111) (99) (51) (35) +15.0%
Free cash flow 46 48 49 62 54 44 (24) (76) (41) 32 50 (3.9%)
Balance, $m
Balance, $m Working capital 257 337 411 489 538 549 440 435 403 446 433 +6.3%
Net debt (144) (211) (268) (343) (380) (380) 643 720 765 608 602 n/m
Shareholders’ equity 472 560 638 725 840 887 3,134 3,144 2,071 2,093 2,086 +18.0%
Returns, %
Returns, % ROA 8.95 11.02 9.16 7.97 7.09 5.05 (0.82) (0.21) (27.33) (0.23) (1.68) (9.2) pt
ROIC 12.37 12.56 11.49 11.03 10.07 7.22 0.62 0.95 (23.38) (0.50) (0.17) (12.9) pt
ROE 10.00 12.24 10.05 8.73 7.78 5.59 (1.14) (0.30) (41.88) (0.38) (2.67) (10.4) pt
People
People Employees 1,413 1,546 1,682 1,764 1,841 2,108 2,640 997 975 817 — (5.9%)
Revenue/emp, $m 0.25 0.26 0.25 0.24 0.25 0.25 0.31 0.93 0.92 1.07 — +17.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 2 Nov 2026

Neogen Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ITGR Integer Holdings Corporation $4.3B 42.2× 38.9× −3.86% (below 0%: shrinking) −61.04% (below 0%: shrinking) −65.19% (below 0%: shrinking) 22.59% 6.27% Compare
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
NEOG Neogen Corporation $2.6B — (loss-making) — (loss-making) +6.50% (above 0%: growing) n/m +135.61% (above 0%: growing) 47.35% (0.81%)
TMDX TransMedics Group, Inc. $2.4B 16.4× 49.4× +41.15% (above 0%: growing) −30.99% (below 0%: shrinking) −55.44% (below 0%: shrinking) 58.45% 13.86% Compare
UFPT UFP Technologies, Inc. $2.3B 30.1× 29.2× +11.57% (above 0%: growing) +25.55% (above 0%: growing) −35.77% (below 0%: shrinking) 29.44% 16.01% Compare
INSP Inspire Medical Systems, Inc. $1.9B 19.1× — (loss-making) −7.93% (below 0%: shrinking) n/m −33.06% (below 0%: shrinking) 86.05% (13.89%) Compare
ESTA Establishment Labs Holdings Inc. $1.9B — (loss-making) — (loss-making) +31.66% (above 0%: growing) n/m +2.75% (above 0%: growing) 70.64% (6.35%) Compare
ALMR Alamar Biosciences, Inc. $1.9B — (loss-making) — (loss-making) +156.24% (above 0%: growing) n/m −20.26% (below 0%: shrinking) 61.54% (45.13%) Compare
BFLY Butterfly Network, Inc. $1.6B — (loss-making) — (loss-making) +51.70% (above 0%: growing) n/m +12.61% (above 0%: growing) 73.02% (41.66%) Compare
Median of peers $2.1B 24.6× 38.9× +28.94% −2.72% −26.66% 66.09% (2.54%)

All 149 Medical Devices stocks →

Neogen Corporation (NEOG) Latest News

5 Nov

Impact 3 · · Zacks

23 Oct

Impact 3 · · StockStory

19 Oct

Impact 4 · · StockStory

13 Oct

Impact 3 · · Bloomberg

8 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · StockStory

7 Oct

Impact 4 · · MarketBeat
Impact 4 · · Business Wire
Impact 4 · · StockStory
Impact 4 · · The Motley Fool transcript
Impact 4 · · TIKR
Impact 4 · · Moby

6 Oct

Impact 4 · · MarketBeat
Impact 4 · · Investing.com
Impact 4 · · Zacks
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Zacks
Impact 3 · · StockStory
Impact 3 · · Associated Press

4 Oct

Impact 3 · · StockStory

2 Oct

Impact 3 · · MarketBeat

1 Oct

Impact 4 · · Zacks
Impact 3 · · Zacks

29 Sep

Impact 3 · · StockStory

28 Sep

Impact 3 · · StockStory

11 Sep

Impact 3 ·

3 Sep

Impact 3 ·

31 Aug

Impact 4 ·

11 Aug

Impact 3 ·

NEOG metrics, ten years each

stockrow.com/NEOG · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com